Spanish neurotechnology SME using eye vergence tracking to enable early, objective detection of ADHD, autism, and cognitive disorders.
Braingaze is a Spanish neurotechnology SME that develops eye-tracking diagnostic tools for detecting and monitoring cognitive and mental health conditions. Their core technology analyzes eye vergence responses — the coordinated movement of both eyes — as measurable biomarkers for conditions including ADHD, autism spectrum disorders, and cognitive decline. They bring clinical neuroscience into a commercial product format, targeting early and objective detection where traditional clinical assessment is slow or subjective. The company sits at the intersection of ophthalmology, neurology, and digital health.
MindTrack (2019) was built entirely around eye vergence responses as a diagnostic signal, and MiND (2015) placed them in a research network studying the same neurodevelopmental populations.
Both projects explicitly target early identification of cognitive conditions — MiND focused on ADHD and autism, MindTrack extended this to broader cognitive and mental disorders.
MiND (2015–2018) embedded Braingaze in a European MSCA training network dedicated to mastering diagnostic and intervention skills for ADHD and autism spectrum disorders.
MindTrack was funded under SME Instrument Phase 1, signalling an active push to validate and commercialize their eye vergence technology as a marketable clinical product.
In their first H2020 project (MiND, 2015–2018), Braingaze participated as a partner in a large MSCA Innovative Training Network, suggesting they were still embedded in the academic research ecosystem and building scientific credibility around ADHD and autism diagnostics. By 2019, they had shifted decisively toward commercial validation: MindTrack was an SME Instrument project they coordinated themselves, applying eye vergence analysis to a broader set of cognitive and mental disorders with an explicit detection-and-monitoring framing. The arc is from scientific contributor in someone else's network to independent technology developer leading their own commercial project.
Braingaze is moving from research participation toward product-led development, and their SME Instrument coordination role suggests they are actively pursuing market validation for their eye-tracking diagnostic platform.
Braingaze has operated in both partner and coordinator roles across just two projects, showing flexibility across consortium types. Their MSCA-ITN participation placed them inside a large multi-partner European training network, while their SME Instrument coordination was likely a leaner, focused effort. This combination suggests they can contribute specialist technology to complex consortia and simultaneously drive smaller, commercially-oriented projects themselves.
Braingaze has connected with 21 unique partners across 9 countries from only 2 projects — a high ratio that reflects the broad consortium structure of their MSCA-ITN participation. Their network spans multiple European countries, giving them an unusually wide reach for a two-project SME.
Braingaze occupies a narrow but defensible niche: an SME with both research-validated expertise and commercial ambition in oculomotor-based neurocognitive diagnostics, a field where most players are either academic labs or large medtech corporations. Unlike university groups working on similar problems, they operate as a commercial entity able to develop and license deployable tools. For consortia targeting digital health, mental health tech, or neurodevelopmental diagnostics, they offer a rare combination of clinical scientific grounding and SME agility.
